Numinus Wellness Inc. (TSX-V:NUMI, OTC:LKYSF) said it has appointed three key advisors - Graham Pechenik, Paul Spagnuolo, and Cory Harris–to its new bioscience advisory board.
The new bioscience advisory board will contribute strategically to advancing Numinus' IP strategy, including product development and clinical trial activities out of the company's Health Canada-licensed research facility, Numinus Bioscience.
It joins Numinus' existing general and clinical advisory boards, comprised of leading industry and subject-matter experts who have been selected to support corporate and therapeutic protocol development. Among them are Gabor Maté, Dennis McKenna, and Zachary Walsh.
READ: Numinus Wellness research facility licensed by Health Canada to supply psilocybin mushrooms
"We are delighted to welcome these experts to our advisory team," said general manager Sharan Sidhu. "These appointments point to the rigour of the research and development that Numinus has already completed and indicate the compelling IP strategy and milestones we anticipate in 2022 and beyond.”
Pechenik is a registered patent attorney and the founder of Calyx Law, a law firm specialized in IP relating to cannabis and psychedelics.
After a decade obtaining and defending patents for Fortune 500 companies across the agricultural, chemical, pharmaceutical, biotech, and technology industries, including working on several landmark patent cases both at trial and on appeal, Pechenik started Calyx Law to help cannabis and psychedelics ventures design and implement their IP strategies. He also contributes to Psilocybin Alpha as editor-at-large, writing about psychedelics IP and contributing to psychedelics patent, legalization, and decriminalization trackers, and is a member of Chacruna's Council for the Protection of Sacred Plants.
Spagnuolo is an associate professor at the University of Guelph and past assistant professor at the University of Waterloo, specialized and award-winning in the development of nutraceuticals as novel therapeutics using cellular biology.
He is a past member of the Natural Health Products Research Society of Canada and has received funding from the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC).
Harris is an associate professor at the University of Ottawa, specializing in the ethnobotany, chemistry and bioactivity of plants. His work involves collaboration with Inuit and First Nations communities, and projects have included investigating the ethical and evidence-based use of alternative medicines and the health benefits and risks of wild plant foods.
"As Numinus Bioscience continues to demonstrate leadership in developing novel products and processes, we see an opportunity to invite expert advisors to help us discover new areas for collaboration and innovation," said Payton Nyquvest, Numinus' CEO in a statement. "These appointments reflect our multidisciplinary thinking and intent to focus on natural products as a major component of our IP strategy, in addition to investigating defensible patent opportunities that support both long-term commercial scaling and safe and equitable access for the public."
Contact Ritika at ritika@proactiveinvestors.com